Difficulty: Medium
Average Score: 88%
Practice
Concurrent use of which of the following drugs may reverse the antiparkinsonian effect of levodopa?
Correct answer
B
Rationale
In the context of pharmacology, it is essential to understand the interactions between drugs to ensure optimal therapeutic outcomes. In this question, the correct answer is B) Bromocriptine. Levodopa is a precursor of dopamine used in the treatment of Parkinson's disease. Bromocriptine, a dopamine agonist, can counteract the antiparkinsonian effects of levodopa by competing for the same receptors, thereby reducing the overall therapeutic efficacy of levodopa.
Option A) Carbidopa is often co-administered with levodopa to prevent its peripheral metabolism, enhancing its central effects without impacting its antiparkinsonian actions. Therefore, carbidopa does not reverse the antiparkinsonian effect of levodopa.
Option C) Selegiline is a monoamine oxidase inhibitor used in Parkinson's disease to prolong the effects of levodopa. It works by inhibiting the breakdown of dopamine, hence enhancing the antiparkinsonian effects of levodopa. Therefore, selegiline does not reverse the antiparkinsonian effect of levodopa.
Option D) All of the above is incorrect because, as explained above, only Bromocriptine can reverse the antiparkinsonian effect of levodopa. Understanding these drug interactions is crucial for healthcare professionals to make informed decisions when managing patients with Parkinson's disease. It highlights the importance of considering the mechanisms of action and potential interactions between drugs to optimize treatment outcomes and minimize adverse effects.
Option A) Carbidopa is often co-administered with levodopa to prevent its peripheral metabolism, enhancing its central effects without impacting its antiparkinsonian actions. Therefore, carbidopa does not reverse the antiparkinsonian effect of levodopa.
Option C) Selegiline is a monoamine oxidase inhibitor used in Parkinson's disease to prolong the effects of levodopa. It works by inhibiting the breakdown of dopamine, hence enhancing the antiparkinsonian effects of levodopa. Therefore, selegiline does not reverse the antiparkinsonian effect of levodopa.
Option D) All of the above is incorrect because, as explained above, only Bromocriptine can reverse the antiparkinsonian effect of levodopa. Understanding these drug interactions is crucial for healthcare professionals to make informed decisions when managing patients with Parkinson's disease. It highlights the importance of considering the mechanisms of action and potential interactions between drugs to optimize treatment outcomes and minimize adverse effects.